Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases

Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO var...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 221; no. 11
Main Authors Rosain, Jérémie, Le Voyer, Tom, Liu, Xian, Gervais, Adrian, Polivka, Laura, Cederholm, Axel, Berteloot, Laureline, Parent, Audrey V, Pescatore, Alessandra, Spinosa, Ezia, Minic, Snezana, Kiszewski, Ana Elisa, Tsumura, Miyuki, Thibault, Chloé, Esnaola Azcoiti, Maria, Martinovic, Jelena, Philippot, Quentin, Khan, Taushif, Marchal, Astrid, Charmeteau-De Muylder, Bénédicte, Bizien, Lucy, Deswarte, Caroline, Hadjem, Lillia, Fauvarque, Marie-Odile, Dorgham, Karim, Eriksson, Daniel, Falcone, Emilia Liana, Puel, Mathilde, Ünal, Sinem, Geraldo, Amyrath, Le Floc'h, Corentin, Li, Hailun, Rheault, Sylvie, Muti, Christine, Bobrie-Moyrand, Claire, Welfringer-Morin, Anne, Fuleihan, Ramsay L, Lévy, Romain, Roelens, Marie, Gao, Liwei, Materna, Marie, Pellegrini, Silvia, Piemonti, Lorenzo, Catherinot, Emilie, Goffard, Jean-Christophe, Fekkar, Arnaud, Sacko-Sow, Aissata, Soudée, Camille, Boucherit, Soraya, Neehus, Anna-Lena, Has, Cristina, Hübner, Stefanie, Blanchard-Rohner, Géraldine, Amador-Borrero, Blanca, Utsumi, Takanori, Taniguchi, Maki, Tani, Hiroo, Izawa, Kazushi, Yasumi, Takahiro, Kanai, Sotaro, Migaud, Mélanie, Aubart, Mélodie, Lambert, Nathalie, Gorochov, Guy, Picard, Capucine, Soudais, Claire, L'Honneur, Anne-Sophie, Rozenberg, Flore, Milner, Joshua D, Zhang, Shen-Ying, Vabres, Pierre, Trpinac, Dusan, Marr, Nico, Boddaert, Nathalie, Desguerre, Isabelle, Pasparakis, Manolis, Miller, Corey N, Poziomczyk, Cláudia S, Abel, Laurent, Okada, Satoshi, Jouanguy, Emmanuelle, Cheynier, Rémi, Zhang, Qian, Cobat, Aurélie, Béziat, Vivien, Boisson, Bertrand, Steffann, Julie, Fusco, Francesca, Ursini, Matilde Valeria, Hadj-Rabia, Smail, Bodemer, Christine, Bustamante, Jacinta, Luche, Hervé, Puel, Anne, Courtois, Gilles, Bastard, Paul, Landegren, Nils, Anderson, Mark S, Casanova, Jean-Laurent
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 04.11.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO variants, from 99 kindreds in 10 countries. Forty-seven of these patients (36%) have auto-Abs neutralizing IFN-α and/or IFN-ω, a proportion 23 times higher than that for age-matched female controls. This proportion remains stable from the age of 6 years onward. On imaging, female patients with IP have a small, abnormally structured thymus. Auto-Abs against type I IFNs confer a predisposition to life-threatening viral diseases. By contrast, patients with IP lacking auto-Abs against type I IFNs are at no particular risk of viral disease. These results suggest that IP accelerates thymic involution, thereby underlying the production of auto-Abs neutralizing type I IFNs in at least a third of female patients with IP, predisposing them to life-threatening viral diseases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
T. Le Voyer, X. Liu, A. Gervais, L. Polivka, A. Cederholm, L. Berteloot, and A.V. Parent contributed equally to this paper.
P. Bastard, N. Landegren, M.S. Anderson, and J.-L. Casanova contributed equally to this paper.
A. Pescatore, E. Spinosa, S. Minic, A.E. Kiszewski, M. Tsumura, C. Thibault, M. Esnaola Azcoiti, J. Martinovic, Q. Philippot, T. Khan, A. Marchal, B. Charmeteau-De Muylder, L. Bizien, and C. Deswarte contributed equally to this paper.
A. Puel and G. Courtois contributed equally to this paper.
Disclosures: A.V. Parent reported personal fees from Thymmune Therapeutics outside the submitted work; in addition, A.V. Parent had a patent to generate thymic epithelial progenitor cells in vitro licensed (Thymmune Therapeutics). J.D. Milner reported personal fees from Blueprint Pharmaceuticals and grants from Pharming outside the submitted work. M.S. Anderson reported other from Merck, Inc. and Medtronic, Inc. outside the submitted work. No other disclosures were reported.
ISSN:0022-1007
1540-9538
1540-9538
DOI:10.1084/jem.20231152